Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity

Short Description:

Chemical Name: Lasofoxifene Tartrate

CAS: 190791-29-8

Appearance: White to Off-White Powder

Chiral Purity: ≥99.0% Purity: ≥98.0% (HPLC)

In the treatment of Postmenopausal Osteoporosis

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply with High Purity and Stable Quality
Chemical Name: Lasofoxifene Tartrate
CAS: 190791-29-8
Lasofoxifene Tartrate (CAS: 190791-29-8) in the treatment of Postmenopausal Osteoporosis

Chemical Properties:

Chemical Name	Lasofoxifene Tartrate
Synonyms	(5R,6S)-5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-2-naphthalenol Tartrate Oporia
CAS Number	190791-29-8
CAT Number	RF-API20
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C28H31NO2.ClH
Molecular Weight	450.019
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Off-White Powder
Moisture (K.F)	≤0.50%
Heavy Metals	≤20ppm
Chiral Purity	≥99.0%
Purity / Analysis Method	≥98.0% (HPLC)
Loss on Drying	≤0.50%
Residue on Ignition	≤0.50%
Test Standard	Chinese Pharmacopoeia (CP); Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API); Postmenopausal Osteoporosis

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Lasofoxifene Tartrate (CAS: 190791-29-8) with high quality.
Lasofoxifene Tartrate is a third-generation, non-steroidal selective estrogen receptor modulator (SERM). It selectively binds to human ERalpha with an IC50 value of 1.5 nM and inhibits bone loss in ovariectomized rats. In clinical studies of postmenopausal osteoporosis, 0.5 mg/day lasofoxifene was associated with reduced risks of nonvertebral and vertebral fractures, ER-positive breast cancer, coronary heart disease, and stroke but an increased risk of venous thromboembolic events. Lasofoxifene has also been shown to act as an inverse agonist at the CB2 cannabinoid receptor, indicating its potential to be repurposed as a therapeutic for indications wherein CB2 is a target.